STUDY00005613: RLUN20119 / A081801 / Chen
Basic Study Information
Purpose:
This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy
versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell
lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies,
such as pembrolizumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,
such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel,
work in different ways to stop the growth of tumor cells, either by killing the cells,
by stopping them from dividing, or by stopping them from spreading. The purpose of
this trial is to find out if the addition of pembrolizumab to usual chemotherapy is
better or worse than usual chemotherapy alone for non-small cell lung cancer.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Yuhchyau Chen
Study Contact Information
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search